Pfizer strikes out on Inlyta expansion bid with postsurgery kidney cancer failure

Pfizer has been looking to expand kidney cancer drug Inlyta's use to renal cell carcinoma (RCC) patients at a high risk of disease recurrence following surgery—but on that front, it's fallen short.